title: The comparison of cyclopentolate and atropine in patients with refractive accommodative esotropia by means of retinoscopy, autorefractometry and biometric lens thickness.
abstract: OBJECTIVE
  In this study, we aimed to compare the cycloplegic effect of cyclopentolate HCI 1% and atropine sulphate 1% in patients with refractive accommodative esotropia by means of retinoscopy, autorefractometer and the measurement of lens thickness by biometry.
  
  
  METHODS
  Thirty-two patients with refractive accommodative esotropia aged from 5 to 10 (mean 6.8+/-1.4), had a deviation under 10 prism diopters, and underwent retinoscopic, autorefractometric and biometric study in dry and wet conditions.
  
  
  RESULTS
  The retinoscopic, autorefractometric and biometric findings of the right eye were 5.10+/-1.21 diopter (D), 5.03+/-1.20 D, 3.43+/-0.16 mm with cyclopentolate, and 5.2+/-1.2 D, 5.2+/-1.2 D, 3.4+/-0.1 mm with atropine. In the left eye, the measurements were 5.2+/-1.4 D, 5.1+/-1.4 D, 3.5+/-0.2 mm with cyclopentolate, and 5.3+/-1.2 D, 5.20+/-1.3 D, 3.4+/-0.2 mm with atropine, respectively. When these obtained data were compared by the Student's t test no statistical significance was found (p > 0.05).
  
  
  CONCLUSIONS
  We suggest that the cyclopentolate cycloplegia applied to the patients with refractive accommodative esotropia is sufficient to produce good cycloplegia, with an effect similar to atropine.
authors.affiliation: Department of Ophthalmology, Firat University, Elaziğ, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Celebi
authors.forename: U
authors.initials: U
authors.lastname: Aykan
mesh_terms: D000065:Accommodation, Ocular / Q000187:drug effects*; D001285:Atropine / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003519:Cyclopentolate / Q000008:administration & dosage / Q000627:therapeutic use*; D004948:Esotropia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007908:Lens, Crystalline / Q000187:drug effects / Q000473:pathology*; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D011680:Pupil / Q000187:drug effects; D012029:Refraction, Ocular / Q000187:drug effects*; D014792:Visual Acuity
chemical_list: D009184:Mydriatics; D009883:Ophthalmic Solutions; D001285:Atropine; D003519:Cyclopentolate